Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints
Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson’s disease fell flat in a clinical trial.